Inhaled bispecific single-domain antibody BM219 for mild-to-moderate COVID-19: a double-blind, randomized, placebo-controlled phase 2 trial.

Publication date: Jul 17, 2025

Open Access PDF

Concepts Keywords
Antibody Antibody
Blind Bispecific
Bm219 Blind
Covid Bm219
Trial Controlled
Covid
Domain
Double
Inhaled
Mild
Moderate
Phase
Placebo
Randomized
Single

Semantics

Type Source Name
disease MESH COVID-19
disease MESH emergency
disease MESH infection
disease IDO nucleic acid
disease IDO symptom
disease IDO blood
disease MESH hypertriglyceridemia
disease MESH lifestyle
disease MESH viral load
drug DRUGBANK Coenzyme M
drug DRUGBANK Ritonavir
disease IDO host
drug DRUGBANK Isoxaflutole
disease MESH viral infections
disease MESH Infectious Diseases
disease MESH Lung Inflammation
pathway REACTOME Reproduction

Original Article

(Visited 1 times, 1 visits today)